Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
IPO Year: 2021
Exchange: NASDAQ
Website: boltbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2022 | $45.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/6/2022 | Overweight → Equal-Weight | Morgan Stanley | |
| 11/10/2021 | $35.00 → $33.00 | Outperform | SVB Leerink |
| 8/16/2021 | $34.00 → $35.00 | Outperform | SVB Leerink |
Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight and set a new price target of $11.00 from $45.00 previously
Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight
SVB Leerink reiterated coverage of Bolt Biotherapeutics with a rating of Outperform and set a new price target of $33.00 from $35.00 previously
SVB Leerink reiterated coverage of Bolt Biotherapeutics with a rating of Outperform and set a new price target of $35.00 from $34.00 previously
SVB Leerink reiterated coverage of Bolt Biotherapeutics with a rating of Outperform and set a new price target of $33.00 from $37.00 previously
SVB Leerink reiterated coverage of Bolt Biotherapeutics with a rating of Outperform and set a new price target of $37.00 from $36.00 previously
SVB Leerink initiated coverage of Bolt Biotherapeutics with a rating of Outperform and set a new price target of $36.00
Morgan Stanley initiated coverage of Bolt Biotherapeutics with a rating of Overweight and set a new price target of $45.00
Guggenheim initiated coverage of Bolt Biotherapeutics with a rating of Buy and set a new price target of $42.00
Stifel Nicolaus initiated coverage of Bolt Biotherapeutics with a rating of Buy and set a new price target of $40.00
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET. Dr. Dumbrava will discuss the results from the Phase 1 dose-escalat
CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced preclinical results from its next-generation Boltbody™ ISACs targeting CEACAM5 and PD-L1 at the American Association for Cancer Research (AACR) Annual Meeting. "We are encouraged by these early results from our next-generation Boltbody™ ISACs targeting CEA a
BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 showed signs of anti-tumor activity, including an unconfirmed partial response, stable disease ≥ 12 weeks in 3/3 non-small cell lung cancer patients and in 2/3 patients at the highest dose Bolt is running a partnering process to advance development of BDC-3042 REDWOOD CITY, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treat
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will present data from the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical study is evaluating BDC-3042 in patients with
BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will be reported in second quarter 2025Cash balance of $70.2 million as of December 31, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended December 31, 2024, and provided a business update. "2024 was a transformational year fo
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: TD Cowen 45th Annual Health Care ConferenceCompany presentation on Tuesday, March 4, 2025 at 3:10 p.m. EST (1:10 p.m. PST) Leerink Partners Global Healthcare ConferenceParticipating in 1x1 meetings on Monday, March 10, 2025 About Bolt Biotherapeutics, Inc.Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics' pipe
-- Targeting Unmet Needs for Treating Solid Tumors-- REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The collaborators are developing a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) targeting Caprin-1, which is applicable to multiple solid tumor types. Under the existing Joint Development and License Agreement, Toray supplies its proprietary antibodies targeting Caprin-1, such as the antibody TRK-950, and Bolt contributes proprietary linker-payloads from its Boltbody™ ISAC platform t
Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersPresented updated preclinical activity of BDC-4182 and key learnings from Phase 1 dose-escalation trial of BDC-1001 at the SITC 39th Annual MeetingBDC-4182 on track to start clinical trial in second quarter 2025Cash balance of $84.4 million as of September 30, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter e
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest Boltbody™ ISACs with enhanced immune activation could offer greater efficacy, warranting further testing REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated preclinical data for BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, and provided key learnings from its Phase 1 do
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O'Callaghan, CEO of Deep Genomics, will be assuming the role of Chair. "Ja
SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13D/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13G - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13D/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13D/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
3 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
DEF 14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
PRE 14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
DEF 14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
S-8 - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
10-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
10-Q - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET. Dr. Dumbrava will discuss the results from the Phase 1 dose-escalat
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Development to oversee all clinical activities; Edith Perez moving to an advisory roleCash balance of $112.8 million now expected to fund the Company into second half 2026, including generation of clinic
Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo® on target to initiate by year end 2021 Live conference call and webcast today at 8:00 a.m. ET/5:00 a.m. PT REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the presentation of interim clinical data from the company's ongoing Phase 1/2 study of BDC-1001, the company's lead immune-stimulat
REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the company will be presenting interim clinical data in a virtual poster on BDC-1001, starting on December 6, 2021 in conjunction with the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2021 taking place on December 8 - 11, 2021. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a HER2-targeting biosimilar of trastuzumab conjug
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O'Callaghan, CEO of Deep Genomics, will be assuming the role of Chair. "Ja
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the "Board") has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his r
REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022. "Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience," said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. "As we continue to advance our immuno-oncology pipeline programs in the clinic, Laura brings important strategic perspective from leading and executing more than 50 transact
REDWOOD CITY, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the appointment of Nicole Onetto, M.D., to its Board of Directors effective Dec. 14, 2021. "Nicole's extensive experience in clinical development and translational research makes her an excellent addition to the Bolt Biotherapeutics Board of Directors. Nicole's work overseeing oncology drug development programs at cancer research institutions, biotechnology and pharmaceutical compan
SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien